Opendata, web and dolomites

RESHAPE SIGNED

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESHAPE project word cloud

Explore the words cloud of the RESHAPE project. It provides you a very rough idea of what is the project "RESHAPE" about.

transdisciplinarity    biomarker    option    recipient    regenerative    basic    overcoming    versus    medicinal    changer    inflammation    treg    record    clinical    models    first    science    adoptive    economic    studies    encouraging    immunity    therapeutic    diseases    function    limited    undesired    allotransplantation    pioneers    ec    vivo    hsc    entities    transfer    presently    technologies    allografts    curative    longtrack    cell    atmp    organ    combat    accompanied    reshape    platforms    backgrounds    crispr    graft    health    tested    cells    limitations    academic    members    broad    tissue    performed    transplantation    transform    host    enhanced    biotech    medicine    suffering    imbalance    functional    preclinical    vitro    disease    stability    care    overcome    patients    data    supports    triple    rejection    regulatory    generation    options    antigen    therapy    trials    stem    1st    game    proven    translation    human    specificity    cas9    conditioning    hematopoietic    immune    reaction    transplant    treatment    fih    gene   

Project "RESHAPE" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 13˙137˙396 €
 EC max contribution 13˙137˙396 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 4˙137˙775.00
2    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) participant 2˙023˙468.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙998˙550.00
4    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 1˙548˙050.00
5    TISSUSE GMBH DE (BERLIN) participant 1˙026˙250.00
6    CELL THERAPY CATAPULT LIMITED UK (LONDON) participant 975˙625.00
7    TXCELL FR (VALBONNE) participant 502˙077.00
8    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 499˙500.00
9    INNOVATION ACTA S.R.L. IT (ROMA) participant 426˙100.00

Map

 Project objective

Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy. Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments. Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation. Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESHAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESHAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More